Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrea Discacciati

Showing results (71-80 of 80) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 80 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 18, 2021
Low-Dose Tamoxifen for Mammographic Density Reduction: A Randomized Controlled TrialMikael Eriksson, Martin Eklund, Signe Borgquist, et al.
Trials|June 27, 2020
The ProBio trial: molecular biomarkers for advancing personalized treatment decision in patients with metastatic castration-resistant prostate cancerAlessio Crippa, Bram De Laere, Andrea Discacciati, et al.
Plos Pathogens|June 23, 2017
Human hantavirus infection elicits pronounced redistribution of mononuclear phagocytes in peripheral blood and airwaysSaskia Scholz, Faezzah Baharom, Gregory Rankin, et al.
The Journal of Urology|July 8, 2025
A Comparison of Stockholm3, Serum Biomarkers, and Risk Calculators to Predict Prostate Cancer in a Racially and Ethnically Diverse Cohort: Evaluation of the Stockholm3 Multiethnic SEPTA Trial: ErratumAlon Lazarovich, Hari Vigneswaran, Thorgerdur Palsdottir, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 22, 2024
Stockholm3 in a Multiethnic Cohort for Prostate Cancer Detection (SEPTA): A Prospective Multicentered TrialHari T Vigneswaran, Martin Eklund, Andrea Discacciati, et al.
The Journal of Urology|April 9, 2025
A Comparison of Stockholm3, Serum Biomarkers, and Risk Calculators to Predict Prostate Cancer in a Racially and Ethnically Diverse Cohort: Evaluation of the Stockholm3 Multiethnic SEPTA TrialAlon Lazarovich, Hari Vigneswaran, Thorgerdur Palsdottir, et al.
European Urology Oncology|April 22, 2025
Prognostic Value of the Circulating Tumor DNA Fraction in Metastatic Castration-resistant Prostate Cancer: Results from the ProBio Platform TrialAlessio Crippa, Bram De Laere, Andrea Discacciati, et al.
BMJ Open|June 6, 2022
I-SPY COVID adaptive platform trial for COVID-19 acute respiratory failure: rationale, design and operationsDaniel Clark Files, Michael A Matthay, Carolyn S Calfee, et al.
Nature Medicine|August 28, 2024
Author Correction: Androgen receptor pathway inhibitors and taxanes in metastatic prostate cancer: an outcome-adaptive randomized platform trialBram De Laere, Alessio Crippa, Andrea Discacciati, et al.
Nature Medicine|August 20, 2024
Androgen receptor pathway inhibitors and taxanes in metastatic prostate cancer: an outcome-adaptive randomized platform trialBram De Laere, Alessio Crippa, Andrea Discacciati, et al.
Pageof 8

Showing results (71-80 of 80) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 80 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 18, 2021
Low-Dose Tamoxifen for Mammographic Density Reduction: A Randomized Controlled TrialMikael Eriksson, Martin Eklund, Signe Borgquist, et al.
Trials|June 27, 2020
The ProBio trial: molecular biomarkers for advancing personalized treatment decision in patients with metastatic castration-resistant prostate cancerAlessio Crippa, Bram De Laere, Andrea Discacciati, et al.
Plos Pathogens|June 23, 2017
Human hantavirus infection elicits pronounced redistribution of mononuclear phagocytes in peripheral blood and airwaysSaskia Scholz, Faezzah Baharom, Gregory Rankin, et al.
The Journal of Urology|July 8, 2025
A Comparison of Stockholm3, Serum Biomarkers, and Risk Calculators to Predict Prostate Cancer in a Racially and Ethnically Diverse Cohort: Evaluation of the Stockholm3 Multiethnic SEPTA Trial: ErratumAlon Lazarovich, Hari Vigneswaran, Thorgerdur Palsdottir, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 22, 2024
Stockholm3 in a Multiethnic Cohort for Prostate Cancer Detection (SEPTA): A Prospective Multicentered TrialHari T Vigneswaran, Martin Eklund, Andrea Discacciati, et al.
The Journal of Urology|April 9, 2025
A Comparison of Stockholm3, Serum Biomarkers, and Risk Calculators to Predict Prostate Cancer in a Racially and Ethnically Diverse Cohort: Evaluation of the Stockholm3 Multiethnic SEPTA TrialAlon Lazarovich, Hari Vigneswaran, Thorgerdur Palsdottir, et al.
European Urology Oncology|April 22, 2025
Prognostic Value of the Circulating Tumor DNA Fraction in Metastatic Castration-resistant Prostate Cancer: Results from the ProBio Platform TrialAlessio Crippa, Bram De Laere, Andrea Discacciati, et al.
BMJ Open|June 6, 2022
I-SPY COVID adaptive platform trial for COVID-19 acute respiratory failure: rationale, design and operationsDaniel Clark Files, Michael A Matthay, Carolyn S Calfee, et al.
Nature Medicine|August 28, 2024
Author Correction: Androgen receptor pathway inhibitors and taxanes in metastatic prostate cancer: an outcome-adaptive randomized platform trialBram De Laere, Alessio Crippa, Andrea Discacciati, et al.
Nature Medicine|August 20, 2024
Androgen receptor pathway inhibitors and taxanes in metastatic prostate cancer: an outcome-adaptive randomized platform trialBram De Laere, Alessio Crippa, Andrea Discacciati, et al.
Pageof 8